Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.31) per share. This is a 64.77 percent increase over losses of $(0.88) per share from the same period last year.
Vera Therapeutics To Present Phase 2a Data On Atacicept In IgA Nephropathy At American Society Of Nephrology Kidney Week 2021 Annual Meeting
Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, announced today the upcoming presentation of
